Tech
Peptide peddlers cheer as RFK Jr. unilaterally grants access, overruling FDA
Publication: Ars Technica - All content
Author: Beth Mole
Source published: 28/10/2026, 22:17:15 UTC
Briefing created: 22/11/2026, 07:29:59 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 29/10/2026, 14:28:24 UTC.
Briefings
In October 2026, Anti-vaccine Health Secretary Robert F. Kennedy unilaterally issued a rule allowing six specific peptide drugs to be sold by specialty pharmacies, overriding FDA scientists who warned of insufficient evidence and potential danger. The rule, titled 'Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances,' was published on October 30, 2026, and applies to compounding pharmacies. Kennedy's Make America Health Again movement and allies frequently use these peptides, with some prominent figures and allies selling them. Kennedy himself uses some peptides and called himself a 'big fan.'
Key points
- Health Secretary Robert F. Kennedy unilaterally passed a rule allowing six specific peptide drugs to be sold by specialty pharmacies, overruling FDA scientists who stated there is insufficient evidence for effectiveness and potential danger.
- The rule, titled 'Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances,' was published on October 30, 2026, and applies to compounding pharmacies, effectively granting them a green light to freely produce and sell the peptides.
Context
Anti-vaccine Health Secretary Robert F. Kennedy has unilaterally passed a rule that will allow specialty pharmacies to sell six specific peptide drugs, overruling scientists at the Food and Drug Administration. The peptides are popular among members of Kennedy's Make America Health Again movement, and many prominent MAHA figures and Kennedy allies sell them. Kennedy said he uses some of the peptides and called himself a 'big fan.'
Limitations
Evidence covers only the October 2026 rule publication and Kennedy's stated use of peptides. Safety concerns from 2023 led to the removal of these peptides from a compounding list; the new rule sidesteps formal reversal of that action. FDA scientists continue to warn of insufficient evidence and potential danger. No data on actual drug efficacy or long-term safety outcomes is provided.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 22/11/2026, 07:29:59 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeigi2iu44ryn6f6mqsonu2cdshpn7acdtwsitvsb3str6vm2acvagi